Denmark· DK-28106147218
Ethosuximide "Orifarm"
A ethosuximide product containing ethosuximid, registered in Denmark by Orifarm Generics A/S. The same ATC class is registered in 16 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Ethosuximide is registered in 16 of 19 countries.
Countries holding a registration under ATC N03AD01 (ethosuximide), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Ethosuximide · ATC N03AD01
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ethosuximide costs, country by country.
Normalised to the WHO defined daily dose (1.25 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ethosuximide · price per daily dose (1.25 g)
USD · FX 28 Sept 2026
- CH Switzerland$1.83
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- ETHOSUXIMID
- Manufacturer
- Orifarm Generics A/S
- Country
- Denmark (DK)
- ATC code
- N03AD01
- ATC class
- Ethosuximide
- Defined daily dose
- 1.25 g, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106147218
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
124 interactions on record for ethosuximide.
Graded by severity as the source publishes them — 124 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ethosuximide · interactions on record
124 records
- 124 moderate
Most severe, free to view
- MetoclopramideA03FA01moderate
- ThiethylperazinA04AB03moderate
- DiphenhydraminA04AB05moderate
- DronabinolA04AD10moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N03AD01
Ethosuximide, as other registers publish it.
- United KingdomEmeside 250mg capsulesFontus Health Ltd
- United KingdomEmeside 250mg/5ml syrupFontus Health Ltd
- United KingdomEpesri 250mg capsulesStrides Pharma UK Ltd
- United KingdomEpesri 250mg/5ml syrupStrides Pharma UK Ltd
- DenmarkEthonorNordic Prime ApS
- DenmarkEthosuximid "2care4"2care4 ApS
- DenmarkEthosuximid "Ebb Medical"Ebb Medical AB
- GermanyEthosuximid GlenmarkGlenmark Arzneimittel Gmbh
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7bc20da1-3e2b-4714-a4fb-52fdb1ae0916 GET /v1/drugs/7bc20da1-3e2b-4714-a4fb-52fdb1ae0916?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "kapsler, bløde",
"source": "dkma",
"strength": "250 mg",
"auth_role": "RMS",
"dk_drugid": "28106147218",
"substance": "ETHOSUXIMID",
"auth_procedure": "Decentral procedure",
"in_medicinpriser": true,
"registration_date_serial": "43720"
}See everything about ethosuximide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.